Results 1 to 10 of about 127,568 (322)

Trans-Septal Myocardial Biopsy in Hypertrophic Cardiomyopathy Using the Liwen Procedure: An Introduction of a Novel Technique [PDF]

Journal of Interventional Cardiology, 2021
Objective. The purpose of this study was to evaluate the feasibility and safety of myocardial biopsy using a new approach, the Liwen procedure. Background.
Chao Han, Mengyao Zhou, Rui Hu, Bo Wang, Lei Zuo, Jing Li, Shengjun Ta, David H. Hsi, Jiani Liu, Lichun Wei, Liwen Liu   +10 more
doaj   +2 more sources

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana, Angelica T. Mejia, Miriam R. Elman, Daniel Kamna, Olives Nguyen, Hailey Volk, Hongya Chen, Ahmad Masri   +7 more
doaj   +2 more sources

Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We report characteristics and outcomes of elderly patients with hypertrophic cardiomyopathy (HCM) with basal septal hypertrophy and dynamic left ventricular outflow tract obstruction.
Alaa Alashi, Nicholas G. Smedira, Zoran B. Popovic, Agostina Fava, Maran Thamilarasan, Samir R. Kapadia, Per Wierup, Harry M. Lever, Milind Y. Desai   +8 more
doaj   +1 more source

Outcomes in Guideline‐Based Class I Indication Versus Earlier Referral for Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background In patients with obstructive hypertrophic cardiomyopathy, surgical myectomy (SM) is indicated for severe symptoms. We sought to compare long‐term outcomes of patients with obstructive hypertrophic cardiomyopathy where SM was based on guideline‐
Alaa Alashi, Nicholas G. Smedira, Kevin Hodges, Zoran B. Popovic, Maran Thamilarasan, Per Wierup, Harry M. Lever, Milind Y. Desai   +7 more
doaj   +1 more source

Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy and Concomitant Aortic Stenosis Undergoing Surgical Myectomy and Aortic Valve Replacement

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Hypertrophic cardiomyopathy (HCM) and aortic stenosis can cause obstruction to the flow of blood out of the left ventricular outflow tract into the aorta, with obstructive HCM resulting in dynamic left ventricular outflow tract obstruction and
Milind Y. Desai, Alaa Alashi, Zoran B. Popovic, Per Wierup, Brian P. Griffin, Maran Thamilarasan, Douglas Johnston, Lars G. Svensson, Harry M. Lever, Nicholas G. Smedira   +9 more
doaj   +1 more source

An overview of the current genetic and phenotypical selection strategies to reduce the prevalence of feline hypertrophic cardiomyopathy = Een overzicht van de huidige genetische en fenotypische selectiestrategieën tegen hypertrofe cardiomyopathie bij de kat [PDF]

, 2020
Hypertrophic cardiomyopathy (HCM) is a common and potentially lethal heart disease in cats. To reduce its prevalence, breeding cats are frequently screened on the basis of their phenotype or genotype.
Broeckx, Bart, Peelman, Luc, Schipper, Tom, Smets, Pascale   +3 more
core   +1 more source

Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters

BMC Cardiovascular Disorders, 2021
Background Light-chain (AL) amyloidosis is the most common type of systemic amyloidosis with poor prognosis. Currently, the predictors of cardiac involvement and prognostic staging systems are primarily based on conventional echocardiography and ...
Changhui Lei, Xiaoli Zhu, David H. Hsi, Jing Wang, Lei Zuo, Shengjun Ta, Qianli Yang, Lei Xu, Xueli Zhao, Yan Wang, Shiren Sun, Liwen Liu   +11 more
doaj   +1 more source

Exercise and hypertrophic cardiomyopathy: Two incompatible entities? [PDF]

, 2020
A greater understanding of the pathogenic mechanisms underpinning hypertrophic cardiomyopathy (HCM) has translated to improved medical care and better survival of affected individuals.
Basu, J, Malhotra, A, Papadakis, M
core   +1 more source

Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy

ESC Heart Failure, 2021
Aims Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM ...
Evan F. Shalen, Stephen B. Heitner, Lana Al‐Rashdan, Reyhaneh Akhavein, Miriam R. Elman, Katherine L. Fischer, Lucy Q. Lin, Meghan Mannello, Babak Nazer, Howard K. Song, Ahmad Masri   +10 more
doaj   +1 more source

First-in-man application of Liwen RF™ ablation system in the treatment of drug-resistant hypertrophic obstructive cardiomyopathy

Frontiers in Cardiovascular Medicine, 2022
ObjectivesThis study sought to evaluate the clinical applicability of the Liwen Liu RF™ ablation system for percutaneous intramyocardial septal radiofrequency ablation (PIMSRA).BackgroundData on new cardiac radiofrequency ablation devices for the ...
Zihao Wang, Rong Zhao, Horst Sievert, Shengjun Ta, Jing Li, Stefan Bertog, Stefan Bertog, Kerstin Piayda, Mengyao Zhou, Changhui Lei, Xiaojuan Li, Jiani Liu, Bo Xu, Bo Feng, Rui Hu, Liwen Liu   +15 more
doaj   +1 more source